Showing 4491-4500 of 6983 results for "".
- Rock Creek Pharmaceuticals Adds KOLs to Enhance Dermatological Disease Programhttps://practicaldermatology.com/news/rock-creek-pharmaceuticals-adds-kols-to-enhance-dermatological-disease-program/2458794/Rock Creek Pharmaceuticals, Inc., a clinical stage drug development company focused on the application of its lead compound being developed to treat chronic inflammatory conditions, has retained two Key Opinion Leaders (KOLs), each having renowned international expertise in dermatological d
- GSK: Positive Phase 3 Results for Benlysta® In Patients with Systemic Lupus Erythematosushttps://practicaldermatology.com/news/gsk-positive-results-phase-3-results-for-benlysta-in-patients-systemic-lupus-erythematosus/2458812/Results from the BLISS-SC Phase 3 pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE) show that Benlysta®(belimumab) 200mg administered weekly via subcutaneous injection plus
- Cosmetic Bootcamp University Exceeds Goalshttps://practicaldermatology.com/news/cosmetic-bootcamp-university-a-success/2458815/Now completing its session in Philadelphia, the Cosmetic Bootcamp University session has exceeded goals, organizers report. Cosmetic Bootcamp seeks to improve patient outcomes in a manner not possible at other meetings by focusing on core specialists in dermatology, plastic surgery, op
- Research Shows Skin Can Reflect Eating Habitshttps://practicaldermatology.com/news/research-shows-skin-can-reflect-eating-habits/2458822/Dermatologists at Baylor College of Medicine say there is evidence that links certain foods to flares in acne. “While there are definitely a number of triggers for acne, the connection between diet and acne is very interesting,” said Dr. Rajani Katta, professor of dermatology
- Phase 3 Data Show Promius Pharma's DFD-01 Met Primary Endpoints for the Treatment of Moderate Psoriasishttps://practicaldermatology.com/news/phase-3-data-show-promius-pharmas-dfd-01-met-primary-endpoints-for-the-treatment-of-moderate-psoriasis/2458833/Findings from two Phase III studies for Promius Pharma’s investigational psoriasis drug DFD-01 show that the agent achieved the primary endpoint at day 15. The primary endpoint was the proportion of patients achieving treatment success at day 15 for both studies. In addition, both stud
- Data Demonstrate Efficacy of ON Light Sciences, Inc.'s DeScribe Transparent PFD Patchhttps://practicaldermatology.com/news/data-demonstrate-efficacy-of-on-light-sciences-incs-describe-transparent-pfd-patch/2458839/Results of a clinical study evaluating the potential role of a Perfluorodecalin (PFD)-infused gel patch in laser-assisted tattoo removal were presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting. “It is estimated that close to 25% of the US population has
- LEO Pharma Inc. Announces FDA Approval of Enstilar Foam for Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-inc-announces-fda-approval-of-enstilar-foam-for-plaque-psoriasis/2458842/The FDA approved LEO Pharma Inc’s Enstilar for the topical treatment of plaque psoriasis in adults 18 years of age and older. Enstilar is a once-daily, alcohol free foam formulation in a pressurized spray can that allows application across large body areas of plaque psoriasis. In th
- MELA Sciences Announces Election of R. Rox Anderson, MD, to Board of Directorshttps://practicaldermatology.com/news/mela-sciences-announces-election-of-r-rox-anderson-md-to-board-of-directors/2458845/R. Rox Anderson, M.D., was elected to the MELA Sciences, Inc.’s board of directors at its Annual General Meeting of Stockholders held on September 30, 2015 in Philadelphia. With Dr. Anderson's election, the MELA board of directors has increased to seven members, six of whom are independ
- Fibrocell and Intrexon: Highlights of Pre-Clinical Data for Potential First-in-Class Treatment for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-and-intrexon-highlights-of-pre-clinical-data-for-potential-first-in-class-treatment-for-recessive-dystrophic-epidermolysis-bullosa/2458847/Fibrocell Science, Inc., and Intrexon Corporation are highlighting a poster entitled “Pre-Clinical Development of a Genetically-Modified Human Dermal Fibroblast (FCX-007) for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)” being presented at the American Society of
- A Novel Dual-Wavelength, Nd:YAG, Picosecond-domain Laser Safely and Effectively Removes Multicolor Tattooshttps://practicaldermatology.com/news/a-novel-dual-wavelength-ndyag-picosecond-domain-laser-safely-and-effectively-removes-multicolor-tattoos/2458848/Research conducted by Eric F. Bernstein MD, MSc; Kevin T. Schomacker PhD; Lisa D. Basilavecchio RN; Jessica M. Plugis; and Jayant D. Bhawalkar PhD, published in the September 2015 issue of Lasers in Surgery and Medicine (LSM), evaluated 21 tattooed subjects between the ages of 19-55 who